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Abstract
A combination of sub-therapeutic chelation and subsequent iron overload are 
regarded as the principal drivers of endocrine dysfunction in thalassaemia. The 
clinical presentation of endocrine complications and their timing of onset can 
be highly variable, in part due to population heterogeneity but also variation in 
chelation strategies. Endocrinopathies commonly associated with thalassaemia 
include: growth delay; pubertal delay; gonadal dysfunction; thyroid disorders; 
parathyroid and adrenal gland impairment; impaired bone metabolism; and type 2 
diabetes mellitus. In this chapter we summarise the main presentations of endocrine 
disorder in thalassaemia, summarising their epidemiology, clinical presentation 
and pathophysiologic basis. Furthermore, we review screening, monitoring and 
treatment strategies, with particular regard to the UK Thalassaemia Society’s 2016 
National Standards.
Keywords: thalassaemia major, beta thalassaemia, endocrinopathy, endocrine 
dysfunction, iron overload, puberty, thyroid, adrenal, diabetes mellitus, bone density
1. Introduction
The inherited haemoglobinopathy thalassaemia major (also known as beta 
thalassaemia major) results from homozygous carriage of mutations at the beta-
globin locus, resulting in defective haemoglobin synthesis and a severe hypochro-
mic, microcytic anaemia. Epidemiologically, the largest incidence of thalassaemia 
major is in the Mediterranean countries and the Middle East, but demographic 
change and international migration have resulted in it posing a global health 
issue. Life expectancy has been radically increased by the advent of combined 
transfusion and chelation therapy, but this regimen is complicated by both citrate 
toxicity and the development of endocrine complications secondary to destructive 
haemosiderin deposition in glandular tissues, particularly during adolescence and 
young adulthood [1]. Pathologic iron deposition is concentrated in cardiac tissue, 
the liver parenchyma and endocrine glands [2], with the development of multiple 
endocrinopathies first being reported by Bannerman and colleagues in 1967 [3]. 
Determining the prevalence and onset patterns of endocrine disease in thalassaemia 
major remains a challenge, despite their high frequency; primarily, this related 
to variation in exposure to chelation therapy, compliance with chelation, and 
improved survival shedding light on new disease phenomena [4–8].
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and review as per 
NICE 9 Key Care 
Processes**
DM: home capillary 
blood glucose as 
per individual 
management plan
• IFG or IGT: fructosamine at 
6-monthly intervals
• Symptomatic hyperglycaemia: 
random plasma glucose ± 




Tests (TFTs)†: free 
TSH, free T3, free T4
• Clinical evidence of thyroid 
dysfunction: random TFTs
Puberty Systematic clinical 











history, no further 
investigations 
indicated





amenorrhoea develop ➔ measure 
LH/FSH/oestradiol. Specialist 
endocrine review advised before 
initiation of hormone replacement.
Growth 6-monthly: height/
weight/height velocity 
from diagnosis to 
attainment of final 
adult height
If concerns regarding growth 
delay: bone age estimation (wrist 
plain radiographs) at 1–2 year 
intervals




Vitamin D level• 6-monthly••: calcium/
phosphate/ALP ➔ 






Key: OGTT: oral glucose tolerance test DM: diabetes mellitus IFG: impaired fasting glycaemia IGT: impaired glucose 
tolerance DKA: diabetic ketoacidosis PTH: parathyroid hormone.
ALP: alkaline phosphatase LH: luteinizing hormone FSH: follicle-stimulating hormone SHBG: sex-hormone binding 
globulin.
*From puberty, or age 10 years if family history of DM.
†From age 12 years.
••From age 12 years.
**NICE 9 Key Care Processes: glycaemic control (via Fructosamine); blood pressure; cholesterol level; retinal 
screening; foot checks; urinary albumin testing; serum creatinine testing; weight monitoring; smoking status check.
‡Including, for female patients, menstrual history; for male patients: history of impotence.
•From age 2 years. UKTS (2016) guidelines recommend ~80 nmol/L optimal target following supplementation.
Table 1. 
Summary of endocrine investigations in thalassaemia major [after UK Thalassaemia Standards, 2016].
Chronic anaemia—and subsequent tissue hypoxia—results in compensatory 
increases in erythropoiesis and gastrointestinal iron absorption. In conjunction 
with regular blood transfusion, these processes conspire to produce massive iron 
deposition in thalassaemia. Iron is regulated exclusively at the level of absorption, 
with no excretory mechanism. Chelation therapies are available, but challenges 
in their administration, including via the parenteral route, and need for regular 
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blood monitoring, hamper their acceptability. The primary endocrine complica-
tions found in thalassaemia, in the order reviewed in this chapter, are: disorders of 
growth; sexual development and fertility; abnormal bone mineralisation; diabetes 
mellitus; hypothyroidism; and hypoadrenalism [9].
We have previously published an online Review of Endocrine Disorders in 
Thalassaemia in 2014 (Open Journal of Endocrine and Metabolic Diseases, 2014, 
4, 25–34). In this book chapter, we have updated all the latest evidence and dis-
cuss current thoughts & details of the multi-system endocrine involvement in 




• Impaired glucose regulation (IFG/
IGT) or Non-insulin treated Diabetes: 
Intensify chelation therapy, consider 
using combination chelation regimens
• Diabetes: Referral to diabetes specialist. 
Managed according to NICE treatment 
targets and recommendations for type 1 
and type 2 diabetes
In patients with symptoms/signs 
of Diabetic Ketoacidosis (DKA) 
who are acutely unwell and plasma 




• Hypothyroidism: thyroxine replacement ✦Hypothyroidism may impair cardiac 
function/rhythm




• Hypogonadism: hormone (oestrogen/
testosterone) replacement
• Females: combined oral contracep-
tive pill (when contraception is also 
required, or “post-menopausal” replace-
ment regime)
✦Specialist endocrine review 
advised before initiation of hormone 
replacement.
Growth • Positive growth hormone stimulation 




• Vitamin D replacement if required
• Bisphosphonates: considered for 
patients with low BMD for age►, fragility 
fractures and/or falling BMD despite 
adequate vitamin D levels
• Denosumab▷: advisable that treatment is 
supervised by a clinical with experience 
and interest in osteoporosis
• Bisphosphonate: should be 
reviewed after a maximum of 
5 years for oral agents and 3 years 
for IV agents. Bisphosphonate 
‘holiday’: is recommended after 




• Adrenal insufficiency: Hydrocortisone 
supplementation
✦Adrenal dysfunction may be 
subacute (during acute illness), 
consider adrenal support, even before 
formal proof of insufficiency is 
available
Key: DM: diabetes mellitus IFG: impaired fasting glycaemia IGT: impaired glucose tolerance DKA: diabetic 
ketoacidosis BMD: Bone Mineral Density GH: growth hormone.
✦Note.
►Z-score < −2.0 if premenopausal or under 50, t-score < −2.5 if post-menopausal or over 50.
▷Anti-RANKL monoclonal antibody.
✥some evidence for GH therapy in childhood only.
Table 2. 
Summary of endocrine treatments in thalassaemia major [after UK Thalassaemia Standards, 2016].
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2. Growth and development in thalassaemia
From the foetal, through to infantile, pre-pubertal period and puberty, children 
with thalassaemia exhibit delayed growth [9]. It is estimated that 20–30% of these 
children and adolescents are affected by growth hormone (GH) deficiency [10]. In 
the remainder of thalassaemic patients without overt growth hormone deficiency, 
provocative testing—for example clonidine or glucagon stimulation tests—suggests 
that peak GH levels are lower than seen in constitutive short stature. Dhouib et al. 
recently showed a 35% incidence of GH deficiency in a Tunisian paediatric cohort 
[11]. Multiple causes for growth failure have been posited. These include features 
directly related to iron overload, including free radical toxicity [12]; damage to 
other endocrine axes, including the GH/Insulin-like growth factor (IGF-1) axis 
[13], pubertal delay and hypothyroidism; and complications of therapy, includ-
ing chelation agent, particularly desferrioxamine, toxicity [14]. Hepatic cirrhosis, 
anaemia and zinc deficiency have also been implicated [15].
The anterior pituitary gland is particularly vulnerable to oxidative stress caused 
by free radicals, with even modest levels of iron deposition, detected by magnetic 
resonance imaging (MRI), disrupting its function [12]. Comparative studies of 
diurnal hormone secretion suggest that the 24-hour profile of GH secretion, and 
the response growth hormone releasing hormone (GHRH, secreted by the arcuate 
nucleus of the hypothalamus), in thalassaemic patients is similar that of children 
with idiopathic short stature [16]. It is posited that thalassaemia major may be 
associated with increased somatostatin tone, with subsequent disruption of GH 
secretion [17].
Thalassaemia major may be characterised by relative growth hormone defi-
ciency, implied by the low levels of serum IGF-1 but normal GH reserve seen in 
patients. The positive therapeutic response seen with exogenous GH supplementa-
tion implies that, at the post-receptor level, this resistance may only be partial 
[18]. Anaemia, ineffecient erythropoiesis and chelation therapy also inhibits linear 
growth in children with thalassaemia major. Desferrioxamine and pathologic iron 
deposition are proposed to disrupt local IGF-1 production and paracrine signalling 
at the growth plate [14], resulting in inhibition of cellular proliferation and mineral 
deposition. Truncal shortening and abnormal body proportions are frequently 
observed, and have been attributed to the disease process itself, compounded by 
iron and desferrioxamine toxicity [18]. Limited evidence is emerging that these 
phenomena may be at least partly contingent on the timing of initiation of chelation 
and its route of administration. Soliman and colleagues reported a cross-sectional 
cohort analysis of beta thalassaemia patients commenced on oral iron chelation 
(OIC) with desferoxamine either before (n = 15) or after (n = 40) attaining final 
adult height. In this small study, pre-pubertal initiation of OIC was correlated with 
increased final adult height, in parallel with a lower overall incidence of endocri-
nopathies and reduced hepatic iron deposition [19].
Karamifar et al. have demonstrated that 62.9% of girls and 69% of boys 
affected with thalassaemia were less than 2SD below the mean for normal height 
[20]. Sharma et al. studied an Indian cohort of beta-thalassaemic children on oral 
desferiprone, of whom 55% were of short stature and 27% had a height z-score 
less than −3 SD. In the subset with height z-score < −3 SD, 17 of 19 patients also 
had severely impaired GH induction in response to dynamic testing with clonidine 
[21]. In one cohort from Germany, 40.6% of patients were defined as being short in 
stature (final adult height < 3rd percentile/below 2 standard deviations [SD] from 
the mean) [22]. Soliman and colleagues replicated this observation, reporting short 
stature (<2SD) in 49% of their thalassaemic patients [23], whereas Borgna-Pignatti 
et al. reported short stature in 37% of their patients [24]. Moayeri et al. showed that 
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62% were less than 2SD and 49% were 3SD below the mean and also confirmed 
decreased growth hormone response to two provocative tests and low levels of 
IGF-1 in a majority of their thalassaemic patients24. Similar reduced responses 
to provocative tests have been reported in studies led by Gulati et al. (51%) and 
Theodiris et al. (20%) [10, 25]. Interestingly, Soliman et al. report that in a small 
sample of adult patients on oral chelation therapy, IGF-1 expression levels did not 
differ significantly between those with normal GH levels and those with GH defi-
ciency, despite significantly lower final adult height in the GH deficient group [19].
Although the results of short term GH therapy are encouraging, the impact 
of treatment on final height of non-GH deficient thalassaemic children remains 
uncertain [18] and often GH produces uncertain clinical response [26, 27]. Ngim et 
al. have undertaken a Cochrane Systematic Review of GH replacement in thalassae-
mia. A single non-randomised trial was eligible, which enrolled 20 Turkish children 
with beta-thalassaemia major, receiving either daily subcutaneous GH or standard 
care. It presented tentative evidence that height velocity may be increased with GH, 
but reported no significant differences in the height standard deviations between 
groups at the study end-point [28]. Most patients lack the pubertal spurt and have 
reduced GH peak amplitude [29], hence responses to recombinant human GH 
therapy is poor when compared with that of children with GH deficiency, idiopathic 
short stature or Turner Syndrome.
The 2016 United Kingdom Thalassemia Society (UKTS) guidelines recommend 
stringent assessment of growth during childhood. This includes recording of height 
(both sitting and standing), weight and height velocity at six-monthly intervals 
until final adult height is attained [30]. Height deficits should prompt referral to 
a paediatric endocrinologist. Plain hand/wrist radiographs at 1–2 year intervals 
until fusion of the epiphyses may aid investigation of faltering height velocity [30]. 
Reduced height velocity, particularly around age 8–12 years, should prompt consid-
eration of both desferrioxamine toxicity and GH deficiency, requiring GH stimula-
tion testing and supplementation if deficient [30].
In contrast to GH deficiency in childhood, GH abnormalities in adults with 
thalassaemia are less well characterised. Recent data from an I-CETA survey 
(International Network of Clinicians for Endocrinopathies in Thalassemia and 
Adolescent Medicine) covering 3314 adult thalassaemia major patients across 
15 international centres, reported a GH deficiency incidence of 3% [31]. The 
discrepancy between this figure and earlier estimates from paediatric cohorts is 
multifactorial. Unlike childhood growth failure, there is no obvious pathological 
correlate of adult growth hormone deficiency to prompt investigation. Adult 
GH deficiency can manifest with neuropsychiatric symptoms; abnormal body 
composition; and cardiac features, including both reduced exercise performance 
[32] and altered myocardial structure [33]. Soliman and colleagues have proposed 
criteria for GH deficiency screening in adults with thalassaemia major. These 
include individuals with high iron loads, short stature (height < −2.5 SDS), low 
serum IGF-1 (< −2 SDS) or existing cardiomyopathy [34]. Given increasing 
survival of patients with thalassaemia major into adulthood, this topic remains in 
need of further investigation.
3. Hypogonadism and puberty in thalassaemia
Sexual immaturity is a profound complication of severe thalassaemia [35]. 
Disruption of the hypothalamic–pituitary-gonadal axis (HPG) may result in 
infertility [36]. While hypogonadism can occur as a result of primary or second-
ary hypogonadism or as a combination of both, multiple studies have shown 
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gonadotropin failure (hypogonadotropic hypogonadism) is the commonest com-
plication [36, 37]. Primary gonadal failure is caused by iron deposition on gonadal 
tissue [37]. Secondary hypogonadism occurs as a result of pituitary gland gonado-
trophic cell iron deposition, as evidenced by GnRH stimulation which demonstrates 
inadequate FSH and LH response [38–40]. Failure of pubertal onset has a very 
high incidence rate, with studies varying between 50–100% [9]. In female patients, 
delayed puberty is defined as a lack of breast development in girls by age 13 and in 
male patients, by a lack of testicular development by age 14 [30].
Delayed puberty in patients with beta thalassaemia major occurs as a result 
of multiple factors. Evidence suggests that the accumulation of excess iron from 
multiple transfusions leads to tissue damage in multiple organs (e.g. the liver, heart, 
endocrine organs), and the presence of free radicals leads to oxidative stress [41]. 
Delays in sexual maturation has been shown to be a result of impaired synthesis of 
leptin caused by the deposition of iron on adipose tissue [42]. Adipose cells response 
to the expression of the ob gene to produce leptin which functions as an indicator to 
instigate puberty. Despite chelation therapy, iron accumulation continues to occur 
in the pituitary, hypothalamus and gonads [43]. The lack of response to gonadotro-
pin releasing hormone in patients with low gonadotropin levels is synonymous with 
hypothalamic and pituitary damage [44].
While MRI assessment of the pituitary gland for iron accumulation has been 
studied with promising results, it is currently not part of routine assessment [45]. In 
terms of growth velocity, patients with thalassaemia were found to have distinctly 
lower or completely absent annual growth rates [46]. Short stature was found in 
up to 20% of such patients [14] and the lack of pubertal growth spurt in puberty, 
whether spontaneous or induced, ultimately adversely affected the attainment of a 
normal final height [18]. Impairment of truncal growth [47] is also compounded by 
disproportionate body ratios and variation in spinal growth. As a result, failure of 
pubertal growth spurt, delayed or absence of sexual development and infertility are 
common sequelae among patients with beta thalassaemia major [36].
Hypogonadism as an endocrine complication in patients with thalassaemia 
major has been reported in multiple studies [36]. A high incidence of hypogonado-
tropic hypogonadism has been found by Chern et al. in their study population [48]. 
A 45% prevalence was found in male patients and 39% in female patients, with an 
overall prevalence of 72%. Of note were significant delays or cessation in develop-
ment of secondary sexual characteristics and the menstrual cycle. These findings 
were reiterated in a cross-sectional study set up in Hong Kong, in which 75% of 
female patients and 62% of male patients were found to have diminished gonadal 
function [13]. In a study conducted of by Saffari et al., hypogonadism was found 
to be the most common endocrine complication. From a study population of 77 
patients, 36 (46.8%) patients were found to have hypogonadism, 28 (36.4%) had 
delayed puberty and in 8 (10.4%) patients there was absence of pubertal progres-
sion [49]. In this study, it was also noted that there was ‘significant correlation 
between bone mineral density and pubertal status (p = 0.001). This study demon-
strates the effects of hypogonadism not only on the reproductive system, but also on 
bone mineral density as well [49].
Failure of puberty was reported by Moayeri et al. in 69% of patients with thalassae-
mia with suppressed FSH and LH levels (73.2% in male patients and 64.8% in female 
patients) [50]. Similar findings were reported in a separate Italian multicentre study, 
which described hypogonadism 47% of female patients and 51% of male patients. 
Hagag et al. demonstrated that in males testosterone levels and testicular volume were 
significantly lower in thalassaemic patients with iron overload [51]. A similar study 
conducted by Hagag et al. in female patients, they showed that FSH, LH and oestrogen 
levels were significantly lower in thalassaemic patients with iron overload [52].
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Pubertal failure has also been described in 73% of male and 42% of female 
patients under the age of 21 years old by Soliman et al. [23]. Similar findings were 
noted by Borgna-Pignatti and colleagues with 67% of males and 38% of females 
experiencing puberty failure [24]. Remarkably, successful conception may still be 
achieved by women who receive adequate chelation therapy.
Bone growth, growth velocity and puberty may be assisted by administration of 
chelation therapy before the commencement of sexual maturation and the use of 
low dose sex steroids in adolescence [9].
Current Standards for the Clinical Care of Children and Adults with 
Thalassaemia UK Guidelines recommend that assessment of gonadal function 
should be done annually throughout adulthood [30]. In men, this would include 
an annual morning testosterone level alongside LH/FSH and SHBG if testosterone 
levels are low. In women, no testing is required in the presence of a normal men-
strual history. However, in the presence of menstrual disturbances, further testing 
(LH/FSH and oestradiol) is recommended [30]. Deficiency should be replaced with 
oestrogen/testosterone while bearing in mind that under-replacement contributes 
to a low bone mineral density. Management is best achieved through a joint multi-
disciplinary consultation between the endocrinologist and thalassaemia team [30].
4. Glucose intolerance and diabetes mellitus
Effective management of patients suffering from homozygous beta thalassaemia 
has led to improved life expectancy and hence manifestations of haemosiderosis 
related complications, notably, disturbances of the exocrine and endocrine function 
of the pancreas [53]. The prevalence of glucose intolerance and diabetes mellitus 
(DM) in patients with homozygous beta thalassaemia has been found to be vari-
able. A retrospective analysis of 92 patients performed by Ang et al. showed that 
diabetes mellitus was one of the most common endocrinopathies with 41% of the 
study population affected [54] while a study conducted by Kanbour et al. reported 
a prevalence of 16.7% for impaired fasting glucose and 12.5% for diabetes mellitus 
[55]. Recently, a meta-analysis conducted by He et al. which included 44 studies 
with 16,605 cases showed that diabetes mellitus was present in 6.54%, impaired 
fasting glucose (IGF) in 17.21% and impaired glucose tolerance (IGT) in 12.46% 
[56]. While the prevalence of glucose intolerance and diabetes mellitus is undoubt-
edly high, many risk factors have also been identified. There was evidence of 
increased risk of diabetes mellitus with co-infection with hepatitis C [55–57], longer 
duration of disease [57–59] and with increased pancreatic iron deposition [58, 60].
Li et al. have found that in addition, patients with diabetes mellitus were charac-
terised by higher ferritin levels, smaller pancreas volume, lower cardiac T2 mag-
netic resonance signal (MRI) than patients without diabetes, and higher prevalence 
of hypogonadism. Interestingly, patients with diabetes were found to be young 
(median age was 22 years [range of 10 to 34 years]) and non-obese (BMI of 20.1 ± 
2.8 kg/m2) [58]. This may explain why the classical association between diabetes 
and increased prevalence of arteriosclerotic cardiovascular disease is not a feature 
in this population [30].
Poor compliance with desferrioxamine therapy (p < 0.05), older age commenc-
ing intensive chelation therapy, liver cirrhosis and severe fibrosis were found to be 
risk factors for glucose intolerance and diabetes mellitus. Risk factors for impaired 
glucose tolerance (IGT) also included male sex [61], poor compliance with desfer-
rioxamine therapy and high hepatic iron concentration.
Current UK guidelines recommend annual monitoring for impaired glucose 
tolerance and diabetes from the onset of puberty, or from the age of 10 years if 
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there is a family history of diabetes [30]. Screening is carried out with the oral 
glucose tolerance test (OGTT) [30]. However, OGTT compliance is often poor. 
This makes the development of adjunct or alternative screening tests of particular 
interest, as detecting pre-clinical diabetes is crucial because the development of 
clinical diabetes can possibly be slowed down or halted. Pancreatic iron overload 
can be assessed by MRI [62] but does not seem to correlate with siderosis in other 
organs. Currently, the relationship between MRI detectable iron and pancreatic 
beta cell dysfunction is not well characterised and MRI of the pancreas for iron 
deposition monitoring is not used clinically [30, 63]. However, there may be scope 
to use cardiac and liver MRI which already have established protocols, for the pur-
pose of screening for impaired glucose tolerance or diabetes. Ang et al. found that 
abnormal myocardial T2 signal may indicate the development of diabetes mel-
litus and other prediabetic states [54]. Li et al. showed similar findings whereby 
Cardiac T2 MRI values were higher in patients with normal fasting glucose levels 
(P = 0.03) [58]. Kanbour et al. found that patients with very high liver iron 
concentration (LIC) (>30 mg Fe/gm dry liver) were more likely to have a higher 
prevalence of impaired fasting glucose when compared to those with lower LIC 
(p = 0.044) [55]. The use of continuous glucose monitoring (CGMS) in detecting 
glucose intolerance and diabetes mellitus has also been studied, with CGMS found 
to be superior when compared to OGTT (p = 0.012) [64]. El-Samahy et al. studied 
20 beta thalassaemia patients with random blood glucose >7.8 mmol, who then had 
OGTT and CGMS. OGTT detected 6/20 patients (30%) who had impaired glucose 
tolerance and 7/20 (35%) patients who were in the diabetic range, while CGMS 
found that 7/20 (35%) patients had IGT and 13/20 (65%) had frank diabetes mel-
litus [64].
In terms of determining overall glycaemic control, UK guidelines recommend 
that serum fructosamine should be used. Fructosamine is a circulating glycated 
protein which measures overall glucose control in the previous 2–3 weeks. HbA1c 
or glycated haemoglobin should be avoided in thalassaemia as it is unreliable in any 
haemoglobinopathy and also after transfusion [30].
Although inadequate insulin release has been reported by several groups  
[60, 65, 66]. Other aetiologies identified include hyperinsulinemia, reduced 
insulin sensitivity [67] and reduction of hepatic insulin release. A study by Siklar 
et al. suggested that development of insulin impairment occurs prior to insulin 
resistance [68]. Furthermore, autoimmunity results in selective oxidative damage 
to beta cells of the pancreas [68]. Beta cells retain their function up to the later 
stages of the disease [9], however insulin sensitivity was found to be inversely 
related to iron overload and age [69]. Fasting pro-insulin and pro-insulin to 
insulin ratios was found to be considerably elevated and have a positive correla-
tion with hepatic iron [70], however C-peptide levels were found to be inconsis-
tent, thus reflecting fluctuating beta cell function [71, 72]. A reduction in serum 
trypsin and lipase levels were found, alongside regular alpha amylase activity. It 
was also found that the development of other endocrine and cardiac complica-
tions were followed by the onset of diabetes mellitus [73]. A 50% decline beta 
cell function was found to be correlated with glucose intolerance, and beta cell 
function was not entirely recovered even after intensive iron chelation. Moreover, 
high transfusion regimes that were not paired with appropriate iron chelation 
could advance the prevalence of diabetes mellitus further.
The prevalence of abnormal glucose metabolism has gradually increased over 
the last 20 years [55]. Therefore, the topic of glucose intolerance and diabetes 
mellitus in patients with thalassaemia major continues to be of significant clinical 
importance.
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5. Thyroid dysfunction
Thyroid dysfunction is a frequently occurring endocrine complication in 
thalassaemia major [39]. Hypothyroidism occurs either as a results of primary 
gland failure, or insufficient thyroid gland stimulation [74]. Hypothyroidism is 
thought to be a graded phenomenon and many types of hypothyroidism have been 
described: (1) sub-biochemical hypothyroidism: which consists of an exaggerated 
TSH response to TRH test in the presence of normal TSH and FT4; (2) sub-clinical 
hypothyroidism: elevated serum TSH with normal serum FT4 levels; (3) overt (clin-
ical) hypothyroidism: High TSH with low FT4 level and (4) central Hypothyrodism: 
an inappropriately low or normal TSH with a low free T4 level [74]. The lack of 
autoimmune thyroiditis in thalassaemia patients continues to be supported by 
multiple studies [75, 76].
Subclinical hypothyroidisim was found to be the most prevalent thyroid dys-
function in many studies [77, 78]. In a study of 144 thalassaemia patients by by 
Saleem et al., hypothyroidism was found in 31.2% of patients. Subclinical hypo-
thyroidism was found to be the most prevalent thyroid dysfunction (31.2%; 45 
patients), whilst only 6.7% [3] patients were found to have overt hypothyroidism. 
Interestingly, 76% of the patients with subclinical hypothyroidism were in the first 
decade of life [77].
The study conducted by Yassouf et al. demonstrated that out of the 82 cases of 
thalassaemia studied, subclinical hypothyroidism was once again found to be the 
most prevalent thyroid disorder - 29.27% of patients [24] had subclinical hypothy-
roidism while only one patient (1.22%) had overt hypothyroidism. In contrast to 
other studies, no case of central hypothyroidism was found [78].
There is a general consensus that central hypothyroidism is underestimated as 
there are only a handful of studies on the topic currently. The diagnosis of central 
hypothyroidism remains difficult from a clinical perspective, as its non-specific 
symptoms means that symptoms are usually attributed to another cause. From a 
biochemical perspective, central hypothyroidism is diagnosed based on a low to 
normal TSH level, in the presence of low levels of free T4 [74].
De Sanctis et al. explored the prevalence of central hypothyroidism in their 
thalassaemia population (339 patients). They found that central hypothyroidism 
was present in 6% of patients aged less than 21 years old, and 7.9% in patients above 
21 years of age. Delaporta et al. showed that 16% of 114 studied patients (mean age 
20.9 ± 7.8 years) had central hypothyroidism [79].
A prospective study carried out by Soliman et al. followed a total of 48 patients 
over a period of 12 years. In this duration, hypothyroidism was diagnosed in 35% 
[17] of patients - central hypothyrodisim was found in 13/17 (76%) patients [75]. 
Unexpectedly, this paper also found that the mean serum ferritin level did not differ 
significantly between patients with or without central hypothyroidism. This in 
turn did not support the hypothesis that iron overload of the HPA axis had resulted 
in central hypothyroidism thus concluding that the precise underlying aetiology 
of central hypothyroidism was unclear. However, due to the susceptibility of the 
pituitary gland to excess iron, central hypothyroidism due to iron overload of the 
HPA axis still remains a possibility [74].
Belhoul et al. found an increase in prevalence of hypothyroidism in splenect-
omised patients [80]. In non-splenectomised thalassemic patients, the spleen was 
thought to have a scavenging effect on free iron fractions. However, further studies 
are needed to evaluate this hypothesis [74].
Thyroid failure was found to correlate with age at which iron chelation therapy 
started. When iron chelation therapy was started late, thyroid dysfunction was 
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found to occur earlier [74]. A study published in 2018 by Upadya et al. showed that 
of a population of 83 children with thalassaemia, 4.8% had evidence of subclinical 
hypothyroidism. In this study, the mean ferritin level was 3983.0 ± 169,830 ng/ml. 
However, while the severity of thyroid dysfunction was statistically significantly 
associated with higher serum TSH value in children in the second decade of life 
(p = 0.001), it is important to note that no significant correlation was found 
between the severity of thyroid dysfunction and serum ferritin levels [76].
These findings were also echoed in the study conducted by Yassouf et al. They 
found that serum ferritin was directly correlated with TSH levels (r = 0.414; 
p < 0.001). However, there was no correlation between serum ferritin and FT4 lev-
els (r = 0.027; p > 0.05) [78]. This study also demonstrated that the risk of thyroid 
dysfunction was increased by non-compliance of chelation therapy by 6.38 fold as 
compared with compliant patients (RR = 6.385 l 95% CI, 2.40–16.95) [78].
In another study a total of 72 thalassaemia patients were followed for 8 years. 
The study endpoint was defined as the incidence of thyroid dysfunction, and aim 
of the study was to analyse ferritin as a prognostic maker. It found that that patients 
with thyroid dysfunction had higher ferritin levels in contrast to those with normal 
thyroid function (1500 (872–2336)) vs. (513 (370–698) ug/l; P < 0.0001). The study 
also found patients with ferritin values above 1800ug/L had a more rapid progres-
sion towards the endpoint of thyroid dysfunction [81].
However, as a single value, ferritin may not always be reliable. Ferritin, as an 
acute phase protein, is subject to fluctuations caused by other variables such as 
inflammation and malignancy. However, ferritin may still be the most convenient 
way to assess iron overload, especially when used as part of a serial measurement 
[81]. Ferritin may be of value as a prognostic maker and may be used to identify 
patients at risk of developing thyroid dysfunction [81]. This begs the question as to 
whether the value of ferritin in determining the severity of thyroid dysfunction is 
over-appreciated [76].
Currently, the UK Thalassaemia Society Standards for the clinical care of chil-
dren and adults with thalassaemia in the UK (2016) recommend thyroid functions 
tests annually in patients with thalassaemia from age of 12 years, or if there are any 
suggestive symptoms of thyroid deficiency between times [30].
6. Hypoparathyroidism
Hypoparathyroidism, resulting in hypocalcaemia, is a late complication of iron 
overload, typically manifesting after the age of 10 years and with a higher incidence 
in men [46]. The first sign of incipient hypoparathyroidism is loss of the diurnal 
pattern of parathyroid hormone (PTH) secretion [9]. The typical biochemical pro-
file is low serum calcium, low serum PTH, low serum vitamin D and elevated serum 
phosphate levels [82]. Clinical signs of the disorder are most frequently noted from 
the second decade of life onwards [15].
A recent survey of clinicians by the International Network of Clinicians for 
Endocrinopathies in Thalassemia and Adolescence Medicine (ICET-A) published in 
2018 reported a prevalence of 6.8% among 3023 thalassaemia major patients from 17 
centres [83]. 42.2% of hypoparathyroid patients in this study were described as asymp-
tomatic at diagnosis. The most common presenting symptom was paraesthesia and/or 
cramping seen in 37.6% patients [83]. In the ICET-A study, 49.8% of [83] hypoparath-
ryoid individuals were also noted to have serum ferritin level > 2.500 ng/ml8. Chirico 
and colleagues also noted a significant association between elevated ferritin and 
incidence of hypoparathyroidism in thalassaemia major, proposing its use a prognostic 
marker for development of endocrinopathy [84].
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Inconsistencies in case definition of hypoparathyroidism have complicated 
estimates of prevalence. In a cohort of transfusion-dependent thalassaemia major 
patients, 13.5% were shown to have hypoparathyroidism, characterised by low 
serum PTH, total and ionised calcium levels [85]. In contrast, a multicentre study 
in Italy, encompassing 25 units, showed the prevalence to be 3.6% [46]. A French 
study from 1993 showed the prevalence of hyperparathyroidism to be as high as 
22.5% [86]; similarly Aleem and colleagues reported a prevalence of 20% [87]. 
Shamshirsaz and colleagues showed a prevalence of 7.6% [1] with male:female 
ratio of 4:1, a higher ratio than has been described elsewhere [46, 83]. Further 
studies in Iran by Bordbar et al. and Bazi et al. reported prevalences of 13.2% [88] 
and 18% [89] respectively among their thalassaemia patient cohorts. Interestingly, 
Tangngam and colleagues reported a prevalence of asymptomatic hypoparathyroid-
ism of 38% in their cohort of 66 transfusion-dependent thalassaemia patients, 
with significantly lower serum FGF-23, a major regulator of phosphate, detected in 
hypoparathyroid patients [90].
A small study by Even and colleagues suggests loss of normal diurnal variation 
in PTH secretion in thalassaemia patients, even in individuals with normal daytime 
calcium levels [91].
In the UK, annual screening of parathyroid function and bone profile is rec-
ommended in thalassaemia patients [30]. Limited data [92, 93] shows that early 
supplementation with Vitamin D or calcitriol treatment for three months is suf-
ficient to normalise plasma calcium and phosphate levels. 2016 UKTS guidelines 
recommend treatment with activated vitamin D preparations in the case of primary 
hypoparathyroidism secondary to iron overload. In order to avoid nephrocalcinosis, 
adjusted calcium levels should be targeted towards the lower reference range [30].
With regard to other complications, tetany, seizures or cardiac failure due to 
severe hypocalcaemia is rare and requires immediate correction with intravenous 
administration of calcium. Koutsis and colleagues report a rare case of Fahr’s 
syndrome—striatopallidodentate calcinosis—in a 42 year-old woman with 
thalassaemia major with erratic compliance with oral vitamin D/calcium supple-
mentation. Her hyperkinetic symptoms resolved with resumption of adequate oral 
 supplementation [94].
7. Adrenal dysfunction
Histological and imaging studies have shown that iron deposits in the adrenal 
cortex of thalassaemic patients are mainly confined to the zona glomerulosa with 
rare involvement of the zona fascicularis [95]. Most studies have revealed intact 
pituitary adrenal axis in thalassaemia patients [35, 60, 65, 66, 96]. Prevalence of 
adrenal insufficiency is variable and depends both on the degree of iron overload, 
cut off values for cortisol measurement and diagnostic test used [97, 98].
Poggi et al. used a low dose synacthen test with adrenal insufficiency deter-
mined by cortisol <500 nmol/L and found a prevalence of 13.7% in the study 
population [97]. Huang et al. used a glucagon stimulation test, followed by cortico-
trophin-releasing hormone and found a prevalence of 61% [98].
Raised ACTH levels were found by McIntosh which suggests primary adrenal 
failure [66], however Costin et al. found suppressed ACTH levels and reduced 
adrenal reserve despite the lack of clinical signs [5]. The diminished ability of the 
adrenal cortex to react to further pulses of ACTH may be reflected in the fact that 
baseline serum and urinary cortisol levels are usually normal [99].
Low serum Dihydroepiandrostenedione (DHEA), Dihydroepiandrostenedione 
Sulphate (DHEAS), androstenedione and testosterone levels were found to be 
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caused by the dissociation between androgen, cortisol and aldosterone synthe-
sis. This may be the reason adrenarche is usually absent in these patients [100]. 
Dysfunctions in ACTH secretion circadian patterns but unaffected cortisol and 
aldosterone secretory were seen in these patients [101]. In addition to that, falsely 
low serum cortisol levels may be found in thalassaemic patients with chronic liver 
disease because cortisol is usually bound to cortisol binding globulin (CBG) which 
is produced by hepatocytes [102]. Currently, there are no reports on CBG levels 
in thalassaemic patients. Nonetheless, the role of CBG in adrenal insufficiency is 
excluded by a normal CBG level in the presence of low cortisol. In female patients, 
oestrogen may cause a rise in CBG levels resulting in inaccurate cortisol levels.
Current research shows female gender to be a protective factor [97]. Huang et 
al. have found that there was a significant prevalence of adrenal insufficiency in 
males when compared to females (92% vs. 29%, p = 0.049) in their study cohort 
[98]. Imaging studies by Drakonaki et al. using MRI scan have frequently identified 
adrenal hypointensity without alteration of morphology in thalassaemia patients 
and verified autopsy findings of correlation between adrenal iron and liver iron 
[103]. However a study by Guzelbey et al., found that, on the contrary, there was 
no statistically significant correlation between iron deposition in the adrenal glands 
and liver [104]. Another study suggests that imaging from Cardiac MRI T2 could be 
used as a surrogate of adrenal hypofunction, with a sensitivity of 81% and specific-
ity of 78% [105]. However, despite high sensitivity, histology still remains the gold 
standard for diagnosis of iron deposition.
Currently, routine cortisol monitoring does not form part of the recommended 
routine investigations to screen for adrenal dysfunction in patients with thalassae-
mia [30]. However, the UK standards for thalassaemia guidelines acknowledges 
that annual monitoring of cortisol may allow for trends in decline to be noted, 
but also stress that normal cortisol levels does not exclude partial adrenal insuf-
ficiency when the patient is unwell. While current literature is very contradictory, 
adrenal dysfunction can be life-threatening in an acutely unwell patient. Therefore, 
hydrocortisone supplementation should be considered even before formal proof of 
insufficiency is available, if clinically relevant [30].
8. Osteoporosis
Beta thalassaemia is associated with marrow expansion, osteopaenia with corti-
cal thickening, trabecular coarsening and bone deformity [106]. Osteoporosis—
defined as a microarchietctual deterioration in bone tissue leading to an increased 
fracture risk [107]—is the predominant bone disease in beta thalassaemia. The 
prevalence of osteoporosis in thalassaemia is variably estimated from 13.6–50% 
[108]. In a cohort of well-treated thalassaemia patients, Baldini and colleagues 
reported demineralization—.osteoporotic or osteopaenic bone—in 92.7% [109].
Factors implicated in its cause include hypogonadism, diabetes mellitus, 
hypothyroidism, hypoparathyroidism, iron overload and its treatment [108, 110]. 
Malnutrition, inadequate exercise and absence of adrenal sex hormones during 
adrenarche and gonadal hormones during puberty are other contributory factors 
[111]. Excessive erythropoesis may also impair bone formation [112]. Iron chelation 
therapy is further linked to hypercalciuria, with consequential nephrolithiasis and 
reduced bone mineral density (BMD) [113]. Desferrioxamine is also linked to bone 
dysplasia, independently of osteoporosis [114].
Spine and hip osteoporosis is common in both sexes, with spinal osteoporosis 
more common in women and the lumbar vertebrae and femoral neck affected more 
frequently in men [110]. Osteoporosis is characterised by significant decreases 
13
Investigation and Management of Endocrinopathies in Thalassaemia Major
DOI: http://dx.doi.org/10.5772/intechopen.93861
in bone mineral density, both cortical and trabecular. In an Italian case series, 
pathological fractures were reported in 19.7% of transfusion-dependent patients 
with thalassaemia major [115]. With regard to putative mechanisms, significantly 
lower osteoprotegerin/RANKL ratios have been observed in thalassaemia patients. 
Excessive RANKL activity favours osteoclastic bone resorption, leading to reduced 
BMD [116]. Sapunarova and colleagues report 10-fold higher serum levels of 
sclerostin, a secreted glycoprotein with anti-osteoblastic properties, in adults with 
transfusion-dependent beta thalassaemia compared to controls [117]. Given its 
correlation with both lumbar spine/femoral neck Z-scores and incidence of fragil-
ity fractures, it has been proposed to act as a biomarker of severe osteoporosis in 
advanced beta thalassaemia. In Tehran, Shamishiraz et al. [1] demonstrated similar 
prevalence of that osteoporosis and osteopaenia in the lumbar spine (50.7% and 
39.4% respectively) of patients with thalassaemia. In the same cohort, osteoporosis 
and osteopaenia prevalences were 10.8% and 36.9% at the femoral neck. These 
prevalences have been replicated in other cohorts [118, 119]. Jensen amd colleagued 
reported “severely low” bone mass in 51% of thalassaemia patients, with “low 
bone mass” in 45% [110]. Among 31 thalassaemic patients studied by Vogiatzi and 
colleagues (5 of whom with the milder thalassaemia intermedia phenotype), 22.6% 
had reduced bone mass (defined as Z score = −1 to −2 on DXA analysis) and 61.3% 
had a low bone mass (Z score ≤ −2) [93].
Early diagnosis requires accurate estimation of BMD via densitometry. 
Interpretation of dual-energy X-ray absorptiometry (DXA) may be confounded 
in thalassaemia due to short stature and spinal deformities caused by medullary 
expansion, bone dysplasia and the increased rate of degenerative vertebral disc 
disease in TM patients [120, 121]. Artefact from hepatic iron loading might also 
derange DXA analysis [122]. Alternative modalities for assessing bone micro-
architecture in thalassaemia include trabecular bone structure (TBS) analysis—a 
textural assessment derived from DXA images—and quantitative computed tomog-
raphy (QCT). These alternative methods remain limited by the distinctive profile 
of thalassaemia osteopathy and, in the case of QCT, by the amount of vertebral iron 
deposition [121, 123].
Prevention, early diagnosis and effective chelation therapy are most effec-
tive in arresting the progression of bone disease in thalassaemia. Tight adherence 
to recommended chelation treatment is required during childhood to prevent 
desferroximine-asssociated bone pathologies, including “pseudo-rickets” and 
cartilaginous dysplasia [30]. Diets rich in calcium and Vitamin D and exercise can 
improve the outcome [69]. The role of lifestyle interventions is particularly promi-
nent during childhood. If deficient, calcium, vitamin D and zinc supplementation 
are advised, preferably via the oral route [119]. 2016 UKTS guidelines advise that 
many patients will require maintenance vitamin D3 supplementation [30]. Annual 
monitoring of vitamin D levels are recommended from age 2 years, aiming for a 
level of approximately 80 nmol/L. Intramuscular depot injection of vitamin D are 
not recommended by UKTS, nor are activated vitamin D preparations (for example 
alfacalcidol) in the absence of proven hypoparathyroidism secondary to iron 
deposition [30].
In terms of anti-osteoclastic treatments, the human anti-RANKL monoclonal 
antibody denosumab has shown promise in a Phase 2b RCT, increasing both lumbar 
spine and wrist BMD in transfusion-dependent TM patients [119]. Data from both 
Indian and Iranian cohorts suggest a role for zolendronic acid in increasing lumbar 
spine BMD [124, 125]. Alendronate and vitamin D regimen showed promise in 
an Italian Phase 2b RCT [126]. Prior to this, Morabito and colleagues showed that 
daily oral alendronate increased BMD in a two-year study of young adults with 
thalassaemia [127]. A 2016 Cochrane review of both bisphosphonates and zinc 
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supplementation for thalassaemia-associated osteoporosis acknowledges an accre-
tion of evidence in favour of their use, but suggests that further RCT evidence is 
required [128].
Current UKTS guidelines advocate consideration of anti-osteoclastic agents 
for individuals with low age-adjusted BMD or in whom fragility fractures have 
occurred despite appropriate vitamin D/calcium or hormone supplementation. 
Bisphosphonate initiation should occur following consultation with a specialist in 
osteoporosis, given that no definite evidence exists for fracture reductions with 
bisphosphonates in thalassaemia patients, despite the evidence for improved BMD. 
Burden of adverse effects, including atypical femoral fractures and osteonecrosis of 
the jaw, are significant [30].
Hormone replacement therapy is beneficial in patients with concomitant 
osteoporosis and hypogonadism but may not offer complete resolution, due to the 
multifactorial nature of bone pathology in thalassaemia [129, 130]. Patients with 
concomitant hypogonadism require hormone replacement therapy [108].
9. Conclusions
There is a high incidence of endocrinological abnormalities in patients with thal-
assaemia. Thalassaemic patients have been shown to have an elevated frequency of 
endocrinopathies in several research centres. The role of regular follow-up to allow 
early detection and proper management of complications is vital. The care and 
quality of life of thalassaemic patients can be positively impacted by advancements 
in transfusion protocols and chelating therapy. Early recognition of endocrinopa-
thies in patients with thalassaemia is crucial apart from the fact that life expectancy 
is increased, at the same time morbidity and mortality as a result of complications 
can be decreased with routine monitoring, appropriate interventions and follow-up 
in thalassaemia-endocrine join care clinics.
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